US20140287061A1 - In-situ cross-linkable polymeric compositions and methods thereof - Google Patents

In-situ cross-linkable polymeric compositions and methods thereof Download PDF

Info

Publication number
US20140287061A1
US20140287061A1 US14/357,342 US201214357342A US2014287061A1 US 20140287061 A1 US20140287061 A1 US 20140287061A1 US 201214357342 A US201214357342 A US 201214357342A US 2014287061 A1 US2014287061 A1 US 2014287061A1
Authority
US
United States
Prior art keywords
polymer
polymeric composition
weight
biocompatible polymeric
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/357,342
Inventor
Joseph A. Landolina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cresilon Inc
Original Assignee
Suneris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suneris Inc filed Critical Suneris Inc
Priority to US14/357,342 priority Critical patent/US20140287061A1/en
Assigned to Suneris, Inc. reassignment Suneris, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LANDOLINA, JOSEPH A
Assigned to Suneris, Inc. reassignment Suneris, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LANDOLINA, JOSEPH A.
Publication of US20140287061A1 publication Critical patent/US20140287061A1/en
Assigned to CRESILON, INC. reassignment CRESILON, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: Suneris, Inc.
Assigned to CRESILON, INC. reassignment CRESILON, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: Suneris, Inc.
Priority to US15/266,813 priority patent/US9687584B1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F283/00—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/04—Alginic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Definitions

  • the present invention relates generally to a composition using a biocompatible polymeric formulation and, in particular, to a hemophilic polymeric matrix for use in wound healing, blood coagulation, and cosmetic use.
  • Wound healing is an intricate, orchestrated process involving the interactions of various cells and matrix components to first establish a provisional tissue and then remodel this while forming the mature replacement.
  • the hemostatic platelet plug reestablishes the infection-limiting and desiccation-limiting barrier, and elicits the first wave of cellular infiltrates.
  • This consists mainly of leukocytes that provide both innate and acquired immunity. These cells produce enzymes and biocidal molecules to eliminate microbial contamination; however, these same defense mechanisms are detrimental to the keratinocytes, fibroblasts and endothelial cells required to regenerate the lost tissue.
  • the events and processes of the inflammatory phase need to regress.
  • a particular challenge is offered in the case of skin wound repair, which occurs at a contaminated surface. If a wound becomes infected, the normal healing is disrupted as the inflammatory phase becomes chronic, suppressing the regenerative phase. Further, the enzymes liberated by both the microbes and leukocytes break down the wound tissue as well as surrounding skin. Thus, it is critical to ensure proper healing to prevent infections being established by normal skin wound contaminants.
  • Fibronectin has been reported to be involved in each stage of the wound healing process, particularly by creating a scaffold to which the invading cells will adhere. Initially, there is a release of many mediators to the wound site, such as fibronectin and fibrinogen. Fibronectin promotes inflammatory cell migration into the wound and debris phagocytosis by monocytes. Thereafter, angiogenesis and reepithelialization take place. At this stage, fibronectin exerts chemotactic activity on endothelial cells, and promotes epithelial cell and fibroblast migration onto the basal membrane. Fibronectin also appears to be essential in the remodeling phase where it plays a major role in the organization of collagen fibrils. The fibrillar collagen ultimately forms fibrous bundles that enhance the tissue tensile strength, leading to would closure.
  • Hydrogels have typically been utilized as topical formulations for promoting the wound healing process.
  • the gel compositions have been selected for their properties of swelling degree, biocompatibility, permeability, and swelling kinetics. Examples of such compounds have included vinyl polymers (e.g. polyacrylic acid), cellulose, and cellulose derivatives.
  • vinyl polymers e.g. polyacrylic acid
  • cellulose e.g. cellulose
  • cellulose derivatives e.g. polyacrylic acid
  • Polyacrylic acid polymer also referred to as carbomer, has been used because of its superiority in delivering fibronectin to skin wounds.
  • Naturally occurring biopolymers have applications in tissue engineering, regenerative medicine, drug delivery, medical implant, plastic surgery, and others.
  • Such products have components including hyaluronic acid (HA), chitosan, heparin, chondroitin sulfate, alginate and other glucosamine and glycosaminoglycans, other polysaccharides, and derivatives thereof.
  • HA hyaluronic acid
  • chitosan chitosan
  • heparin chondroitin sulfate
  • alginate and other glucosamine and glycosaminoglycans other polysaccharides, and derivatives thereof.
  • fibronectin and similar proteins
  • alginate salt concentrations of fibronectin (and similar proteins) have been utilized with alginate salt to treat chronic ulcers.
  • the dressing system has been solidified, converting the gel into fibers, by a process of freeze-drying. This procedure creates a sponge-like structure with hydrophilic properties.
  • the dressings can return to a gel-like state, absorbing up to 20 times their weight in wound exudate.
  • the dressing is easily removed after the wound treatment because of its sponge-like structure and moisture retention.
  • the fibronectin-cellulose dressing does not provide the desired fibrous protective film on the surface of the deepithelialized human skin. Debridement is then performed upon removal of the dressing to remove any necrotic material.
  • Chronic wounds which would assist healing, decrease inflammation, reduce pain, and prevent scar formation with both acute and chronic wounds.
  • acute wounds that could be treated include burns, abrasions, dry skin, post-op surgical incisions, cuts, puncture wounds, blisters, insect bites, and other severe tissue injury.
  • Chronic wound treatment might encompass slow to heal wounds including pressure ulcers, venous ulcers, diabetic foot ulcers, decubitus ulcers, and non-healing tissue injuries.
  • composition that will be easily applied, forming a matrix conducive to the healing of a tissue, and having anti-microbial properties.
  • the composition may be biocompatible or quickly reacted to avoid possibilities of cytotoxicity. Further, the composition will stimulate and maximize wound healing while providing a controlled method for providing thin and thick layers of a solidified wound dressing, as desired.
  • Indirect effects may include reduced need for medical procedures such as debridement, decreased hospitalization time, reduced postoperative recovery times, shortened return interval to daily functions and work, and reduced overall treatment costs. Desirably, these improvements to wound healing, including application and method of use, will be valuable in treating and repairing various tissue(s).
  • the following invention is a biocompatible polymeric composition that is a gelatinous wound healing and hemostatic matrix able to be formed and solidified both internally and externally.
  • the biocompatible polymeric composition comprises 1) one or more than one polyanionic polymer and 2) one or more than one polycationic polymer.
  • the one or more than one polyanionic polymer includes at least one cross-linkable polyanionic polymer.
  • the one or more than one polyanionic polymer includes at least one cross-linkable polyanionic polymer and at least one non-cross-linkable polyanionic polymer.
  • the biocompatible polymeric composition comprises a mixture of 1) one or more than one polyanionic polymer able to be formed on the surface of a wound and 2) one or more than one polycationic polymer that assists in the solidification process as well as speeds up blood clotting.
  • the biocompatible polymeric composition comprises a mixture of 1) one or more than one polyanionic polymer able to be formed on the surface of a wound; 2) one or more than one polycationic polymer that assists in the solidification process as well as speeds up blood clotting; and 3) a cross-linking mist that cross-links the gel in the wound while disinfecting the surrounding area.
  • the one or more than one polyanionic polymer comprises alginates or hyaluronates. In one embodiment of the invention, the one or more than one polycationic polymer comprises chitosan. In one embodiment of the invention, the cross-linking mist may be aqueous calcium chloride.
  • One or more methods of using the medical gel of the invention are also disclosed, including rapidly achieving hemostasis without the need to apply pressure, and providing a biocompatible wound healing matrix.
  • Various embodiments of the invention allow the formulation to be adjusted and implemented for varying the desired viscosity and pre-determined characteristic functions.
  • the ratio of the polycationic polymer to the polyanionic polymer may be improved, having varying degrees of efficiency in wound healing.
  • therapeutics can be added to integrate drug formulations for drug delivery options.
  • other features may encompass controlling temperature(s) and/or pressure(s) during the preparation of the medical gel, during application of the gel, and implementing a control for the elasticity or rigidity of the solidified matrix.
  • the matrix formulation, both liquid and solidified structures, may also be dependent on anatomical and physiological measurements and conditions.
  • compositions allow the composition to be adjusted and implemented at a first tissue site or a second tissue site, and such modification deemed obvious may be integrated and combined in varying quantities to provide for a structural matrix of any size, shape, and configuration.
  • FIG. 1 is a side view of an embodiment of the present invention.
  • FIG. 2 is a microscopic depiction of how the present invention interacts with blood and itself.
  • FIGS. 3A to 3I show various polymeric subunits that can be used to make up the polycationic or polyanionic polymers.
  • FIG. 4 shows the benefits of the present invention as compared to existing technology.
  • Biocompatible polymeric compositions of the present invention may be used to treat external wounds as well as internal wounds.
  • the biocompatible polymeric composition may be applied to a variety of wounds.
  • wounds include, but are not limited to: an external laceration, an abrasion, a burn, an ocular laceration, damage to a parenchymal organ, an internal laceration, a laceration in the gastrointestinal tract, superficial cuts and scrapes, internal bleeding, an arterial bleed, a venous bleed, dental or oral bleeds and incisions.
  • Subjects who can benefit from such wound treatment include a variety of animals including humans, mammals such as horses, sheep, cattle, hogs, dogs, cats, and marine animals such as whales, dolphins, seals, otters, fish, and reptiles such as turtles.
  • FIG. 1 An illustration of a structural matrix in accordance with one embodiment of the invention is shown in FIG. 1 .
  • a damaged section of tissue, wound ( 112 ) has vasculature ( 116 ) protruding throughout.
  • a biocompatible polymeric composition ( 114 ) has been applied to the wound ( 112 ), which has been coated with protective coat ( 110 ).
  • FIG. 2 shows a magnified view of one embodiment of biocompatible polymeric composition ( 114 ), which comprises structural polymer ( 226 ) and hemophilic polymer ( 224 ).
  • Structural polymer ( 226 ) comprises about 0.1% to 95% by total composition weight of a cross-linkable polyanionic polymer and 0% to 95% by total composition weight of a non-cross-linkable polyanionic polymer.
  • Hemophilic polymer ( 224 ) comprises about 1% to 90% by total composition weight of a polycationic polymer.
  • Red blood cell ( 210 ) is shown in relation to the cationic function groups ( 212 ) via a red blood cell-cationic group linkage ( 216 ).
  • FIGS. 3A to 3I show various polymers that can be chosen as structural polymer ( 226 ) or hemophilic polymer ( 224 ). Polymers can be modified through the addition of carboxymethyl (CM) groups to gain anionic functional groups ( 218 ).
  • FIG. 3E shows carboxymethyl cellulose. Alginate ( 3 A), sodium hyaluronate ( 3 F), ⁇ -carrageenan ( 3 G), ⁇ -carrageenan ( 3 H), and sodium polyacrylate ( 3 I) are examples of polymers that would function as structural polymer ( 226 ).
  • chitin ( 3 B) and chitosan ( 3 C) are examples of polymers that would function as hemophilic polymer ( 224 ).
  • FIG. 3D shows how any polymer ( 340 ) can be modified with a diethylaminoethyl (DEAE) group to gain cationic functional groups ( 212 ).
  • DEAE diethylaminoethyl
  • Biocompatible polymeric composition ( 114 ) contains about 0.1% to 99.8% by total composition weight of a solvent.
  • the solvent is ethanol.
  • the solvent is a 5% aqueous solution of ethanol in water.
  • Non-limiting examples of solvents include water, ethanol, amyl acetate, acetone, methyl ethyl ketone, isopropanol, and tetrahydrofuran.
  • structural polymer ( 226 ) and hemophilic polymer ( 224 ) experience intermolecular interactions which bind them together.
  • hemophilic polymer ( 224 ) attract anionic functional groups ( 218 ) on structural polymer ( 226 ) and result in ionic cross-linking ( 214 ). Additionally, hemophilic polymer ( 224 ) and structural polymer ( 226 ) can be covalently cross-linked ( 228 ), similar to a Schiff base or azomethine linkage.
  • Protective coat ( 110 ) comprises 0.1% to 30% by weight of a di- or higher valent cation ( 220 ), 0% to 90% by weight of a hydrophobic polymer, and 5% to 99.9% by weight of a solvent.
  • Protective coat ( 110 ) cross-links composition ( 114 ) by diffusing divalent cation ( 220 ) inwards, which results in divalent cation cross-linking ( 222 ) of structural polymer ( 226 ). This increases the rigidity of composition ( 114 ) and allows for better stability.
  • Protective coat ( 110 ) can also contain hydrophobic polymers, which limit the water loss from composition ( 114 ) and improve durability.
  • the hydrophobic polymer may be a polyurethane, nitrocellulose, a cyanoacrylate, a styrene, a polytetrafluoroethane, and a silicone, and combinations thereof.
  • the solvent may be water, amyl acetate, acetone, methyl ethyl ketone, isopropanol, and tetrahydrofuran, and combinations thereof.
  • the di- or higher valent cation may be Ca2+, Fe2+, Fe3+, Ag2+, Ag3+, Au2+, Au3+, Mg2+, Cu2+, Cu3+, and Zn2+. In one embodiment of the invention, the cation is Ca2+.
  • structural polymer ( 226 ) comprises 0.1% to 5% by weight of sodium alginate and 1% to 5% by weight of sodium hyaluronate
  • hemophilic polymer ( 224 ) comprises 2% to 25% by weight of chitosan chloride
  • the solvent comprises 65% to 96.9% by weight of a 5% aqueous solution of ethanol in water.
  • the composition functions as a wound healing matrix to facilitate faster tissue regeneration.
  • structural polymer ( 226 ) comprises 2% to 5% by weight of sodium alginate and 0% to 2% by weight of sodium hyaluronate
  • hemophilic polymer ( 224 ) comprises 5% to 20% by weight of chitosan chloride
  • the solvent comprises 73% to 93% by weight of a 5% aqueous solution of ethanol in water.
  • the composition functions as a thick gel for rapidly achieving hemostasis without the need to apply pressure.
  • the composition can be delivered topically to the compromised blood vessel.
  • structural polymer ( 226 ) comprises 0.1% to 4% by weight of sodium alginate and 1% to 5% by weight of a lysine-rich polypeptide
  • hemophilic polymer ( 224 ) comprises 5% to 25% by weight of diethylaminoethyl-dextran (DEAE-Dextran)
  • the solvent comprises 65% to 93% by weight of a 5% aqueous solution of ethanol in water.
  • the biocompatible polymeric composite ( 114 ) is then cross-linked in situ by applying an aerosol mist comprising 0.1% to 1% by weight of calcium chloride, 1% to 5% by weight of nitrocellulose, and 94% to 98.9% by weight of amyl acetate.
  • the composition functions as a protective covering for cuts and scrapes that is durable and limits water loss from the wound.
  • the biocompatible polymeric composition comprises about 3.6% by weight of sodium alginate, about 7% by weight of chitosan chloride, and about 89.4% by weight of a 5% aqueous solution of ethanol in water.
  • This embodiment may function as a composition to treat arterial bleeds.
  • the protective coat comprises a solution comprising about 0.1% to about 30% by weight of a di- or higher valent cation; 0% to about 90% by weight of a hydrophobic polymer; and about 5% to about 99.9% by weight of a solvent.
  • the protective coat comprises a solution comprising about 0.1% to about 1% by weight of a di-valent cation; about 1 to about 5% by weight of a hydrophobic polymer; and about 94% to about 98.9% by weight of a solvent.
  • composition ( 114 ) is used as a carrier for a therapeutic agent such as a drug or biologic molecule.
  • a therapeutic agent such as a drug or biologic molecule.
  • protective coat ( 110 ) is prepared with a salt of silver, increasing the antimicrobial properties of the gel.
  • the therapeutic agent is selected from the group consisting of: antimicrobial agents, antibiotics, hormones, proteins (such as calreticulin, thrombin, prothrombin, Factor VIII), and iodine, and combinations thereof.
  • the therapeutic agent is preferably iodine.
  • the therapeutic agent is a protein.
  • the cross-linkable polyanionic polymer may be a polystyrene sulfonate (such as sodium polystyrene sulfonate), a polyacrylate (such as sodium polyacrylate), a polymethacrylate (such as sodium polymethacrylate), a polyvinyl sulphate (such as sodium polyvinyl sulphate), a polyphosphate (such as sodium polyphosphate), Iota carrageenan, Kappa carrageenan, gellan gum, carboxyl methyl cellulose, carboxyl methyl agarose, carboxyl methyl dextran, carboxyl methyl chitin, carboxyl methyl chitosan, a polymer modified with a carboxyl methyl group, an alginate (such as sodium alginate), a polymer containing a plurality of carboxylate groups, a xanthan gum, and combinations thereof.
  • the crosslinkable polyanionic polymer is an alginate (such as sodium alg
  • the cross-linkable polyanionic polymer comprises about 1% to about 95% by weight of the biocompatible polymeric composition; preferably the cross-linkable polyanionic polymer comprises about 5% to about 40% by weight of the biocompatible polymeric composition; preferably the cross-linkable polyanionic polymer comprises about 10% to about 30% by weight of the biocompatible polymeric composition.
  • the non-cross-linkable polyanionic polymer may be a hyaluronate (such as sodium hyaluronate), a polynucleotide (such as RNA), a polypeptide chain having an average residue isoelectric point below 7, a glucosaminoglycan, and a proteoglycan, and combinations thereof.
  • a hyaluronate such as sodium hyaluronate
  • RNA polynucleotide
  • a polypeptide chain having an average residue isoelectric point below 7 a glucosaminoglycan
  • proteoglycan and combinations thereof.
  • the non-cross-linkable polyanionic polymer is a hyaluronate, more preferably sodium hyaluronate.
  • the non-cross-linkable polyanionic polymer comprises about 0 to about 95% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 5 to about 25% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 0 to about 5% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 0 to about 2% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 1 to about 5% by weight of the biocompatible polymeric composition.
  • the polycationic polymer may be a chitosan (such as chitosan chloride), chitin, diethylaminoethyl-dextran, diethylaminoethyl-cellulose, diethylaminoethyl-agarose, diethylaminoethyl-alginate, a polymer modified with a diethylaminoethyl group, a polymer containing a plurality of protonated amino groups, and a polypeptide having an average residue isoelectric point above 7, and combinations thereof.
  • the polycationic polymer is a chitosan, more preferably chitosan chloride.
  • the polycationic polymer is diethylaminoethyl-dextran (DEAE-Dextran).
  • the polycationic polymer comprises about 1% to about 90% by weight of the biocompatible polymeric composition; preferably the polycationic polymer comprises about 2% to about 80% by weight of the biocompatible polymeric composition; preferably the polycationic polymer comprises about 2% to about 25% by weight of the biocompatible polymeric composition.
  • the individual components of the biocompatible polymeric composition may be stored in a variety of different containers for a variety of different applications, including for example, packets, sachets, tubes, tubs, pumps, syringes, bottles, bags, and aerosol-based spray cans.
  • the components may be stored in containers made of a variety of materials, including for example, plastic, metal, or glass.
  • the components may be provided in operably connected configurations, or as separate components for a user to set up prior to use.
  • compositions and systems described herein may be included in a kit or article of manufacture for forming a biocompatible polymeric composition
  • a biocompatible polymeric composition comprising one or more of: a solution comprising a polyanionic polymer; a solution comprising a polycationic polymer; a solvent; and a solution comprising a di- or higher valent cation, a hydrophobic polymer, and solvent.
  • the kit or article of manufacture may further contain gauze, bandages, tape, brushes, spatulas, and sponges.
  • the studies described may utilize one embodiment of the composition to form a rigid matrix while another composition may be designed with an increased elasticity, alone or in combination. Further, the methods of mixing and formulating the composition may be performed in any order and combination so as to achieve the same or similar effects of the embedded solidified matrix, the matrix integrating the formation of naturally restructuring tissue.
  • the one or more than one polyanionic polymer is first applied to a wound and then the one or more than one polycationic polymer is applied to the said one or more than one polymeric polymer at the wound site.
  • the one or more than one polyanionic polymer is mixed with the one or more than one polycationic polymer and then the mixture is then applied to the wound.
  • the one or more than one polyanionic polymer is applied to a wound at the same time, or about the same time, that the one or more than one polycationic polymer is applied to a wound.
  • a method of treating a wound comprises applying one or more than one polyanionic polymer to a wound and then applying one or more than one polycationic polymer to the said one or more than one polymeric polymer at the wound site.
  • a method of treating a wound comprises mixing one or more than one polyanionic polymer with one or more than one polycationic polymer and then applying the mixture to the wound.
  • a method of treating a wound comprises applying one or more than one polyanionic polymer to the wound at the same time, or about the same time, as one or more than one polycationic polymer is applied to a wound.

Abstract

A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition.

Description

  • This application claims the benefit of provisional patent application Ser. No. 61/559,110, filed 13 Nov. 2011, the entire disclosure of which is incorporated herein by reference.
    • FIELD OF THE INVENTION
  • The present invention relates generally to a composition using a biocompatible polymeric formulation and, in particular, to a hemophilic polymeric matrix for use in wound healing, blood coagulation, and cosmetic use.
    • BACKGROUND OF THE INVENTION
  • Wound healing is an intricate, orchestrated process involving the interactions of various cells and matrix components to first establish a provisional tissue and then remodel this while forming the mature replacement. Initially, the hemostatic platelet plug reestablishes the infection-limiting and desiccation-limiting barrier, and elicits the first wave of cellular infiltrates. This consists mainly of leukocytes that provide both innate and acquired immunity. These cells produce enzymes and biocidal molecules to eliminate microbial contamination; however, these same defense mechanisms are detrimental to the keratinocytes, fibroblasts and endothelial cells required to regenerate the lost tissue. Thus, as healing proceeds, the events and processes of the inflammatory phase need to regress.
  • A particular challenge is offered in the case of skin wound repair, which occurs at a contaminated surface. If a wound becomes infected, the normal healing is disrupted as the inflammatory phase becomes chronic, suppressing the regenerative phase. Further, the enzymes liberated by both the microbes and leukocytes break down the wound tissue as well as surrounding skin. Thus, it is critical to ensure proper healing to prevent infections being established by normal skin wound contaminants.
  • Wound healing is usually divided into three phases: the inflammatory phase, the proliferative phase, and the remodeling phase. Fibronectin has been reported to be involved in each stage of the wound healing process, particularly by creating a scaffold to which the invading cells will adhere. Initially, there is a release of many mediators to the wound site, such as fibronectin and fibrinogen. Fibronectin promotes inflammatory cell migration into the wound and debris phagocytosis by monocytes. Thereafter, angiogenesis and reepithelialization take place. At this stage, fibronectin exerts chemotactic activity on endothelial cells, and promotes epithelial cell and fibroblast migration onto the basal membrane. Fibronectin also appears to be essential in the remodeling phase where it plays a major role in the organization of collagen fibrils. The fibrillar collagen ultimately forms fibrous bundles that enhance the tissue tensile strength, leading to would closure.
  • Hydrogels have typically been utilized as topical formulations for promoting the wound healing process. The gel compositions have been selected for their properties of swelling degree, biocompatibility, permeability, and swelling kinetics. Examples of such compounds have included vinyl polymers (e.g. polyacrylic acid), cellulose, and cellulose derivatives. Polyacrylic acid polymer, also referred to as carbomer, has been used because of its superiority in delivering fibronectin to skin wounds.
  • Naturally occurring biopolymers have applications in tissue engineering, regenerative medicine, drug delivery, medical implant, plastic surgery, and others. Such products have components including hyaluronic acid (HA), chitosan, heparin, chondroitin sulfate, alginate and other glucosamine and glycosaminoglycans, other polysaccharides, and derivatives thereof.
  • In combination, concentrations of fibronectin (and similar proteins) have been utilized with alginate salt to treat chronic ulcers. The dressing system has been solidified, converting the gel into fibers, by a process of freeze-drying. This procedure creates a sponge-like structure with hydrophilic properties. In the presence of fluids, the dressings can return to a gel-like state, absorbing up to 20 times their weight in wound exudate. The dressing is easily removed after the wound treatment because of its sponge-like structure and moisture retention. However, once hydrated with saline solution, the fibronectin-cellulose dressing does not provide the desired fibrous protective film on the surface of the deepithelialized human skin. Debridement is then performed upon removal of the dressing to remove any necrotic material.
  • Thus, problems exist in the treatment of acute and chronic wounds, including delayed healing, reduced granulation and epithelialization, and persistent wound inflammation. Compromised wound healing can result in other complications and problems, such as infection, pain, and development of chronic (non-healing) wounds.
  • Current needs exist in the treatment of chronic wounds which would assist healing, decrease inflammation, reduce pain, and prevent scar formation with both acute and chronic wounds. Such acute wounds that could be treated include burns, abrasions, dry skin, post-op surgical incisions, cuts, puncture wounds, blisters, insect bites, and other severe tissue injury. Chronic wound treatment might encompass slow to heal wounds including pressure ulcers, venous ulcers, diabetic foot ulcers, decubitus ulcers, and non-healing tissue injuries.
  • Overall, a composition is desired that will be easily applied, forming a matrix conducive to the healing of a tissue, and having anti-microbial properties. The composition may be biocompatible or quickly reacted to avoid possibilities of cytotoxicity. Further, the composition will stimulate and maximize wound healing while providing a controlled method for providing thin and thick layers of a solidified wound dressing, as desired.
  • Indirect effects may include reduced need for medical procedures such as debridement, decreased hospitalization time, reduced postoperative recovery times, shortened return interval to daily functions and work, and reduced overall treatment costs. Desirably, these improvements to wound healing, including application and method of use, will be valuable in treating and repairing various tissue(s).
    • SUMMARY OF THE INVENTION
  • The following invention is a biocompatible polymeric composition that is a gelatinous wound healing and hemostatic matrix able to be formed and solidified both internally and externally.
  • In one embodiment of the invention, the biocompatible polymeric composition comprises 1) one or more than one polyanionic polymer and 2) one or more than one polycationic polymer. In one embodiment of the invention, the one or more than one polyanionic polymer includes at least one cross-linkable polyanionic polymer. In another embodiment of the invention, the one or more than one polyanionic polymer includes at least one cross-linkable polyanionic polymer and at least one non-cross-linkable polyanionic polymer.
  • In one embodiment of the invention, the biocompatible polymeric composition comprises a mixture of 1) one or more than one polyanionic polymer able to be formed on the surface of a wound and 2) one or more than one polycationic polymer that assists in the solidification process as well as speeds up blood clotting. In another embodiment of the invention, the biocompatible polymeric composition comprises a mixture of 1) one or more than one polyanionic polymer able to be formed on the surface of a wound; 2) one or more than one polycationic polymer that assists in the solidification process as well as speeds up blood clotting; and 3) a cross-linking mist that cross-links the gel in the wound while disinfecting the surrounding area.
  • In one embodiment of the invention, the one or more than one polyanionic polymer comprises alginates or hyaluronates. In one embodiment of the invention, the one or more than one polycationic polymer comprises chitosan. In one embodiment of the invention, the cross-linking mist may be aqueous calcium chloride.
  • One or more methods of using the medical gel of the invention are also disclosed, including rapidly achieving hemostasis without the need to apply pressure, and providing a biocompatible wound healing matrix.
  • Various embodiments of the invention allow the formulation to be adjusted and implemented for varying the desired viscosity and pre-determined characteristic functions. In one aspect, the ratio of the polycationic polymer to the polyanionic polymer may be improved, having varying degrees of efficiency in wound healing. In another aspect, therapeutics can be added to integrate drug formulations for drug delivery options. Further, other features may encompass controlling temperature(s) and/or pressure(s) during the preparation of the medical gel, during application of the gel, and implementing a control for the elasticity or rigidity of the solidified matrix. The matrix formulation, both liquid and solidified structures, may also be dependent on anatomical and physiological measurements and conditions.
  • Various embodiments of the invention allow the composition to be adjusted and implemented at a first tissue site or a second tissue site, and such modification deemed obvious may be integrated and combined in varying quantities to provide for a structural matrix of any size, shape, and configuration.
    • DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a side view of an embodiment of the present invention.
  • FIG. 2 is a microscopic depiction of how the present invention interacts with blood and itself.
  • FIGS. 3A to 3I show various polymeric subunits that can be used to make up the polycationic or polyanionic polymers.
  • FIG. 4 shows the benefits of the present invention as compared to existing technology.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • In the following detailed description, for purposes of explanation and not limitation, exemplary embodiments disclosing specific details are set forth in order to provide a thorough understanding of the present invention. However, it will be apparent to one having ordinary skill in the art that the present invention may be practiced in other embodiments that depart from the specific details disclosed herein. In other instances, detailed descriptions of well-known compositions and methods may be omitted so as not to obscure the description of the present invention.
  • Biocompatible polymeric compositions of the present invention may be used to treat external wounds as well as internal wounds. In one embodiment of the invention, the biocompatible polymeric composition may be applied to a variety of wounds. Non-limiting examples of wounds include, but are not limited to: an external laceration, an abrasion, a burn, an ocular laceration, damage to a parenchymal organ, an internal laceration, a laceration in the gastrointestinal tract, superficial cuts and scrapes, internal bleeding, an arterial bleed, a venous bleed, dental or oral bleeds and incisions. Subjects who can benefit from such wound treatment include a variety of animals including humans, mammals such as horses, sheep, cattle, hogs, dogs, cats, and marine animals such as whales, dolphins, seals, otters, fish, and reptiles such as turtles.
  • An illustration of a structural matrix in accordance with one embodiment of the invention is shown in FIG. 1. As depicted, a damaged section of tissue, wound (112), has vasculature (116) protruding throughout. A biocompatible polymeric composition (114) has been applied to the wound (112), which has been coated with protective coat (110).
  • FIG. 2 shows a magnified view of one embodiment of biocompatible polymeric composition (114), which comprises structural polymer (226) and hemophilic polymer (224). Structural polymer (226) comprises about 0.1% to 95% by total composition weight of a cross-linkable polyanionic polymer and 0% to 95% by total composition weight of a non-cross-linkable polyanionic polymer. Hemophilic polymer (224) comprises about 1% to 90% by total composition weight of a polycationic polymer. Red blood cell (210) is shown in relation to the cationic function groups (212) via a red blood cell-cationic group linkage (216).
  • FIGS. 3A to 3I show various polymers that can be chosen as structural polymer (226) or hemophilic polymer (224). Polymers can be modified through the addition of carboxymethyl (CM) groups to gain anionic functional groups (218). FIG. 3E shows carboxymethyl cellulose. Alginate (3A), sodium hyaluronate (3F), κ-carrageenan (3G), τ-carrageenan (3H), and sodium polyacrylate (3I) are examples of polymers that would function as structural polymer (226). Likewise, chitin (3B) and chitosan (3C) are examples of polymers that would function as hemophilic polymer (224). FIG. 3D shows how any polymer (340) can be modified with a diethylaminoethyl (DEAE) group to gain cationic functional groups (212).
  • Biocompatible polymeric composition (114) contains about 0.1% to 99.8% by total composition weight of a solvent. In one embodiment of the invention, the solvent is ethanol. Preferably the solvent is a 5% aqueous solution of ethanol in water. Non-limiting examples of solvents include water, ethanol, amyl acetate, acetone, methyl ethyl ketone, isopropanol, and tetrahydrofuran. In solution, structural polymer (226) and hemophilic polymer (224) experience intermolecular interactions which bind them together. Cationic function groups (212) on hemophilic polymer (224) attract anionic functional groups (218) on structural polymer (226) and result in ionic cross-linking (214). Additionally, hemophilic polymer (224) and structural polymer (226) can be covalently cross-linked (228), similar to a Schiff base or azomethine linkage.
  • Protective coat (110) comprises 0.1% to 30% by weight of a di- or higher valent cation (220), 0% to 90% by weight of a hydrophobic polymer, and 5% to 99.9% by weight of a solvent. Protective coat (110) cross-links composition (114) by diffusing divalent cation (220) inwards, which results in divalent cation cross-linking (222) of structural polymer (226). This increases the rigidity of composition (114) and allows for better stability. Protective coat (110) can also contain hydrophobic polymers, which limit the water loss from composition (114) and improve durability. The hydrophobic polymer may be a polyurethane, nitrocellulose, a cyanoacrylate, a styrene, a polytetrafluoroethane, and a silicone, and combinations thereof. The solvent may be water, amyl acetate, acetone, methyl ethyl ketone, isopropanol, and tetrahydrofuran, and combinations thereof. The di- or higher valent cation may be Ca2+, Fe2+, Fe3+, Ag2+, Ag3+, Au2+, Au3+, Mg2+, Cu2+, Cu3+, and Zn2+. In one embodiment of the invention, the cation is Ca2+.
  • In one embodiment of the invention, structural polymer (226) comprises 0.1% to 5% by weight of sodium alginate and 1% to 5% by weight of sodium hyaluronate, hemophilic polymer (224) comprises 2% to 25% by weight of chitosan chloride, and the solvent comprises 65% to 96.9% by weight of a 5% aqueous solution of ethanol in water. In this embodiment, the composition functions as a wound healing matrix to facilitate faster tissue regeneration.
  • In another embodiment, structural polymer (226) comprises 2% to 5% by weight of sodium alginate and 0% to 2% by weight of sodium hyaluronate, hemophilic polymer (224) comprises 5% to 20% by weight of chitosan chloride, and the solvent comprises 73% to 93% by weight of a 5% aqueous solution of ethanol in water. In this embodiment, the composition functions as a thick gel for rapidly achieving hemostasis without the need to apply pressure. The composition can be delivered topically to the compromised blood vessel.
  • In another embodiment of the invention, structural polymer (226) comprises 0.1% to 4% by weight of sodium alginate and 1% to 5% by weight of a lysine-rich polypeptide, hemophilic polymer (224) comprises 5% to 25% by weight of diethylaminoethyl-dextran (DEAE-Dextran), and the solvent comprises 65% to 93% by weight of a 5% aqueous solution of ethanol in water. The biocompatible polymeric composite (114) is then cross-linked in situ by applying an aerosol mist comprising 0.1% to 1% by weight of calcium chloride, 1% to 5% by weight of nitrocellulose, and 94% to 98.9% by weight of amyl acetate. In this embodiment, the composition functions as a protective covering for cuts and scrapes that is durable and limits water loss from the wound.
  • In one embodiment of the invention, the biocompatible polymeric composition comprises about 3.6% by weight of sodium alginate, about 7% by weight of chitosan chloride, and about 89.4% by weight of a 5% aqueous solution of ethanol in water. This embodiment may function as a composition to treat arterial bleeds.
  • In one embodiment of the invention, the protective coat comprises a solution comprising about 0.1% to about 30% by weight of a di- or higher valent cation; 0% to about 90% by weight of a hydrophobic polymer; and about 5% to about 99.9% by weight of a solvent. In one embodiment of the invention, the protective coat comprises a solution comprising about 0.1% to about 1% by weight of a di-valent cation; about 1 to about 5% by weight of a hydrophobic polymer; and about 94% to about 98.9% by weight of a solvent.
  • In one embodiment of the invention, composition (114) is used as a carrier for a therapeutic agent such as a drug or biologic molecule. The use of composition (114) as a drug delivery system improves the efficiency of the wound healing gel. In one aspect, protective coat (110) is prepared with a salt of silver, increasing the antimicrobial properties of the gel. In one embodiment, the therapeutic agent is selected from the group consisting of: antimicrobial agents, antibiotics, hormones, proteins (such as calreticulin, thrombin, prothrombin, Factor VIII), and iodine, and combinations thereof. In one embodiment of the invention, the therapeutic agent is preferably iodine. In another embodiment of the invention, the therapeutic agent is a protein.
  • In one embodiment of the invention, the cross-linkable polyanionic polymer may be a polystyrene sulfonate (such as sodium polystyrene sulfonate), a polyacrylate (such as sodium polyacrylate), a polymethacrylate (such as sodium polymethacrylate), a polyvinyl sulphate (such as sodium polyvinyl sulphate), a polyphosphate (such as sodium polyphosphate), Iota carrageenan, Kappa carrageenan, gellan gum, carboxyl methyl cellulose, carboxyl methyl agarose, carboxyl methyl dextran, carboxyl methyl chitin, carboxyl methyl chitosan, a polymer modified with a carboxyl methyl group, an alginate (such as sodium alginate), a polymer containing a plurality of carboxylate groups, a xanthan gum, and combinations thereof. Preferably, the crosslinkable polyanionic polymer is an alginate, more preferably sodium alginate.
  • Preferably the cross-linkable polyanionic polymer comprises about 1% to about 95% by weight of the biocompatible polymeric composition; preferably the cross-linkable polyanionic polymer comprises about 5% to about 40% by weight of the biocompatible polymeric composition; preferably the cross-linkable polyanionic polymer comprises about 10% to about 30% by weight of the biocompatible polymeric composition.
  • In one embodiment of the invention, the non-cross-linkable polyanionic polymer may be a hyaluronate (such as sodium hyaluronate), a polynucleotide (such as RNA), a polypeptide chain having an average residue isoelectric point below 7, a glucosaminoglycan, and a proteoglycan, and combinations thereof. Preferably the non-cross-linkable polyanionic polymer is a hyaluronate, more preferably sodium hyaluronate.
  • Preferably the non-cross-linkable polyanionic polymer comprises about 0 to about 95% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 5 to about 25% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 0 to about 5% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 0 to about 2% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 1 to about 5% by weight of the biocompatible polymeric composition.
  • In one embodiment of the invention, the polycationic polymer may be a chitosan (such as chitosan chloride), chitin, diethylaminoethyl-dextran, diethylaminoethyl-cellulose, diethylaminoethyl-agarose, diethylaminoethyl-alginate, a polymer modified with a diethylaminoethyl group, a polymer containing a plurality of protonated amino groups, and a polypeptide having an average residue isoelectric point above 7, and combinations thereof. Preferably the polycationic polymer is a chitosan, more preferably chitosan chloride. Preferably the polycationic polymer is diethylaminoethyl-dextran (DEAE-Dextran).
  • Preferably the polycationic polymer comprises about 1% to about 90% by weight of the biocompatible polymeric composition; preferably the polycationic polymer comprises about 2% to about 80% by weight of the biocompatible polymeric composition; preferably the polycationic polymer comprises about 2% to about 25% by weight of the biocompatible polymeric composition.
  • The individual components of the biocompatible polymeric composition may be stored in a variety of different containers for a variety of different applications, including for example, packets, sachets, tubes, tubs, pumps, syringes, bottles, bags, and aerosol-based spray cans. The components may be stored in containers made of a variety of materials, including for example, plastic, metal, or glass. The components may be provided in operably connected configurations, or as separate components for a user to set up prior to use.
  • The compositions and systems described herein may be included in a kit or article of manufacture for forming a biocompatible polymeric composition comprising one or more of: a solution comprising a polyanionic polymer; a solution comprising a polycationic polymer; a solvent; and a solution comprising a di- or higher valent cation, a hydrophobic polymer, and solvent. The kit or article of manufacture may further contain gauze, bandages, tape, brushes, spatulas, and sponges.
  • A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of this document. In particular, for example, various compositions of the solutions have been described, but varying similar components and elements may be integrated or utilized in substitution to achieve the same or similar effect. Moreover, varying matrices may be employed to target diverse wound locations, internal or external to the dermal layers of the skin, including organ transplantation, tissue grafting, and/or various surgical incisions and lesions at any site or location external and/or internal to the body. Accordingly, other implementations are within the scope of the following claims.
  • Further, the studies described may utilize one embodiment of the composition to form a rigid matrix while another composition may be designed with an increased elasticity, alone or in combination. Further, the methods of mixing and formulating the composition may be performed in any order and combination so as to achieve the same or similar effects of the embedded solidified matrix, the matrix integrating the formation of naturally restructuring tissue. In one embodiment, the one or more than one polyanionic polymer is first applied to a wound and then the one or more than one polycationic polymer is applied to the said one or more than one polymeric polymer at the wound site. In one embodiment, the one or more than one polyanionic polymer is mixed with the one or more than one polycationic polymer and then the mixture is then applied to the wound. In one embodiment, the one or more than one polyanionic polymer is applied to a wound at the same time, or about the same time, that the one or more than one polycationic polymer is applied to a wound.
  • In one embodiment, a method of treating a wound comprises applying one or more than one polyanionic polymer to a wound and then applying one or more than one polycationic polymer to the said one or more than one polymeric polymer at the wound site. In one embodiment, a method of treating a wound comprises mixing one or more than one polyanionic polymer with one or more than one polycationic polymer and then applying the mixture to the wound. In one embodiment, a method of treating a wound comprises applying one or more than one polyanionic polymer to the wound at the same time, or about the same time, as one or more than one polycationic polymer is applied to a wound.

Claims (21)

What is claimed:
1. A biocompatible polymeric composition comprising:
a. about 0.1% to about 95% by weight of one or more than one polyanionic polymer;
b. about 0.1% to about 90% by weight of one or more than one polycationic polymer; and
c. 0.1% to 99.8% by weight water.
2. A biocompatible polymeric composition of claim 1 wherein the one or more than one polyanionic polymer comprises at least one cross-linkable polyanionic polymer.
3. A biocompatible polymeric composition of claim 2 wherein the one or more than one polyanionic polymer further comprises at least one non-cross-linkable polyanionic polymer.
4. A biocompatible polymeric composition of claim 3, wherein at least one cross-linkable polyanionic polymer is selected from the group consisting of: a polystyrene sulfonate, a polyacrylate, a polymethacrylate, a polyvinyl sulphate, a polyphosphate, Iota carrageenan, Kappa carrageenan, gellan gum, carboxyl methyl cellulose, carboxyl methyl agarose, carboxyl methyl dextran, carboxyl methyl chitin, carboxyl methyl chitosan, a polymer modified with a carboxyl methyl group, an alginate, a polymer containing a plurality of carboxylate groups, and xanthan gum.
5. A biocompatible polymeric composition of claim 4, wherein one or more than one cross-linkable polyanionic polymer is selected from the group consisting of: sodium polystyrene sulfonate, sodium polyacrylate, sodium polymethacrylate, sodium polyvinyl sulphate, sodium polyphosphate, and sodium alginate.
6. A biocompatible polymeric composition as in claim 3, wherein at least one non-cross-linkable polyanionic polymer is selected from the group consisting of: a hyaluronate, a polynucleotide, a polypeptide chain having an average residue isoelectric point below 7, a glucosaminoglycan, and a proteoglycan.
7. A biocompatible polymeric composition as in claim 6, wherein at least one non-cross-linkable polyanionic polymer is selected from the group consisting of: sodium hyaluronate or RNA.
8. A biocompatible polymeric composition as in claim 3, wherein the one or more than one polycationic polymer is selected from the group consisting of: chitosan, chitin, diethylaminoethyl-dextran, diethylaminoethyl-cellulose, diethylaminoethyl-agarose, diethylaminoethyl-alginate, a polymer modified with a diethylaminoethyl group, a polymer containing a plurality of protonated amino groups, and a polypeptide having an average residue isoelectric point above 7.
9. A biocompatible polymeric composition as in claim 3, wherein at least one cross-linkable polyanionic polymer is cross-linked to at least one polycationic polymer through hydrogen bonding.
10. A biocompatible polymeric composition as in claim 3, wherein at least one cross-linkable polyanionic polymer is cross-linked to at least one polycationic polymer through covalent linkages.
11. A biocompatible polymeric composition as in claim 3 further comprising a therapeutic agent selected from the group consisting of: antimicrobial agents, antibiotics, hormones, proteins, and iodine.
12. A method of forming a protective coat over a polymeric composition of claim 1 in situ, comprising the addition of a solution comprising:
a. about 0.1% to about 30% by weight of a di- or higher valent cation;
b. 0% to about 90% by weight of a hydrophobic polymer; and
c. about 5% to about 99.9% by weight of a solvent
13. A method of claim 12, wherein said hydrophobic polymer is selected from the group consisting of: a polyurethane, nitrocellulose, a cyanoacrylate, a styrene, a polytetrafluoroethane, and a silicone.
14. A method of claim 12, wherein said solvent is selected from the group consisting of:
water, amyl acetate, acetone, methyl ethyl ketone, isopropanol, and tetrahydrofuran.
15. A method of claim 12, wherein said di- or higher valent cation is selected from the group consisting of salts of: Ca2+, Fe2+, Fe3+, Ag2+, Ag3+, Au2+, Au3+, Mg2+, Cu2+, Cu3+, and Zn2+.
16. A method of treating a wound comprising directly applying to a wound a biocompatible polymeric composition of claim 1.
17. A method of claim 16, wherein said wound is selected from the group consisting of:
an external laceration, an abrasion, a burn, an ocular laceration, damage to a parenchymal organ, an internal laceration, a laceration in the gastrointestinal tract, superficial cuts and scrapes, internal bleeding, an arterial bleed, a venous bleed, dental or oral bleeds and incisions.
18. A method of achieving rapid hemostasis without the need to apply pressure to a wound comprising directly applying to a wound a biocompatible polymeric composition of claim 1.
19. A biocompatible polymeric composition comprising:
a. about 1% to about 20% by weight of sodium alginate;
b. about 1% to about 5% by weight of sodium hyaluronate;
c. about 2% to about 20% by weight of chitosan chloride; and
d. 55% to 96% by weight of a 5% aqueous solution of ethanol in water.
20. A method of forming a protective coat over a polymeric composition of claim 19 in situ, comprising the addition of a solution comprising:
a. about 0.1% to about 1% by weight of calcium chloride;
b. about 1% to about 5% by weight of nitrocellulose; and
c. about 94% to about 98.9% by weight of amyl acetate.
21. A biocompatible polymeric composition as in claim 1, wherein said solvent is selected from the group consisting of: water, ethanol, amyl acetate, acetone, methyl ethyl ketone, isopropanol, and tetrahydrofuran.
US14/357,342 2011-11-13 2012-11-12 In-situ cross-linkable polymeric compositions and methods thereof Abandoned US20140287061A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/357,342 US20140287061A1 (en) 2011-11-13 2012-11-12 In-situ cross-linkable polymeric compositions and methods thereof
US15/266,813 US9687584B1 (en) 2011-11-13 2016-09-15 In-situ cross-linkable polymeric compositions and methods thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559110P 2011-11-13 2011-11-13
PCT/US2012/064670 WO2013071235A1 (en) 2011-11-13 2012-11-12 In-situ cross-linkable polymeric compositions and methods thereof
US14/357,342 US20140287061A1 (en) 2011-11-13 2012-11-12 In-situ cross-linkable polymeric compositions and methods thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/064670 A-371-Of-International WO2013071235A1 (en) 2011-11-13 2012-11-12 In-situ cross-linkable polymeric compositions and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/266,813 Continuation US9687584B1 (en) 2011-11-13 2016-09-15 In-situ cross-linkable polymeric compositions and methods thereof

Publications (1)

Publication Number Publication Date
US20140287061A1 true US20140287061A1 (en) 2014-09-25

Family

ID=48290658

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/357,342 Abandoned US20140287061A1 (en) 2011-11-13 2012-11-12 In-situ cross-linkable polymeric compositions and methods thereof
US15/266,813 Active US9687584B1 (en) 2011-11-13 2016-09-15 In-situ cross-linkable polymeric compositions and methods thereof
US15/611,418 Active US10850003B2 (en) 2011-11-13 2017-06-01 In-situ cross-linkable polymeric compositions and methods thereof
US17/084,518 Active US11383005B2 (en) 2011-11-13 2020-10-29 In-situ cross-linkable polymeric compositions and methods thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/266,813 Active US9687584B1 (en) 2011-11-13 2016-09-15 In-situ cross-linkable polymeric compositions and methods thereof
US15/611,418 Active US10850003B2 (en) 2011-11-13 2017-06-01 In-situ cross-linkable polymeric compositions and methods thereof
US17/084,518 Active US11383005B2 (en) 2011-11-13 2020-10-29 In-situ cross-linkable polymeric compositions and methods thereof

Country Status (16)

Country Link
US (4) US20140287061A1 (en)
EP (1) EP2776068A4 (en)
JP (3) JP2014533181A (en)
KR (1) KR20140090670A (en)
CN (2) CN109602944A (en)
AU (2) AU2012334982A1 (en)
BR (1) BR112014011442A8 (en)
CA (1) CA2855347C (en)
HK (1) HK1201734A1 (en)
IL (1) IL232330B (en)
IN (1) IN2014CN03524A (en)
MX (2) MX366366B (en)
RU (2) RU2640084C2 (en)
SG (2) SG11201402279SA (en)
WO (1) WO2013071235A1 (en)
ZA (1) ZA201403166B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173971B2 (en) 2010-11-12 2015-11-03 University Of Utah Research Foundation Simple adhesive coacervates and methods of making and using thereof
US9272069B2 (en) 2008-01-24 2016-03-01 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
WO2016209198A1 (en) * 2015-06-22 2016-12-29 Cresilion, Inc. Highly efficacious hemostatic adhesive polymer scaffold
US20170128263A1 (en) * 2014-07-11 2017-05-11 National Institutes Of Health Surgical tool and method for ocular tissue transplantation
US9867899B2 (en) 2010-05-24 2018-01-16 University Of Utah Research Foundation Reinforced adhesive complex coacervates and methods of making and using thereof
US9913926B2 (en) 2008-01-24 2018-03-13 University Of Utah Research Foundation Adhesive complex coacervates and method of making and using thereof
US9913927B2 (en) 2014-07-14 2018-03-13 University Of Utah Research Foundation In situ solidifying complex coacervates and methods of making and using thereof
WO2018119320A1 (en) * 2016-12-21 2018-06-28 Cresilon, Inc. Hemostatic compositions with antifibrinolytic agents
US10077324B2 (en) 2013-02-06 2018-09-18 Kci Licensing, Inc. Polymers, preparation and use thereof
US20190328933A1 (en) * 2018-01-26 2019-10-31 Polarityte, Inc. Composite-interfacing biomaterial accelerant substrate
US10660945B2 (en) 2015-08-07 2020-05-26 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US10850003B2 (en) 2011-11-13 2020-12-01 Cresilon, Inc. In-situ cross-linkable polymeric compositions and methods thereof
US11065337B2 (en) 2015-12-14 2021-07-20 University of Pittsburgh—of the Commonwealth System of Higher Education Complex coacervate for controlled release and related methods
US11266678B2 (en) * 2016-08-25 2022-03-08 Pharmaresearch Co., Ltd. Composition for articular cavity injection comprising nucleic acid and chitosan
US11298423B2 (en) * 2016-03-04 2022-04-12 University of Pittsburgh—of the Commonwealth System of Higher Education Protection and delivery of multiple therapeutic proteins
US11541151B2 (en) 2017-09-20 2023-01-03 Cha University Industry-Academic Cooperation Foundation Coacervate composition containing protein drug and wound healing agent comprising same
US11896234B2 (en) 2018-01-26 2024-02-13 Fluidx Medical Technology, Llc Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20130375A1 (en) * 2013-05-10 2014-11-11 Marco Benzi PRODUCT FOR USE FOR THERAPEUTIC TREATMENT OF PARODONTOPATHIES AND PERIMPLANTS
CN103611180B (en) * 2013-11-21 2015-02-18 无锡中科光远生物材料有限公司 Preparation method of self-adhesion hemostasis anti-adhesion corpus fibrosum
CN105030815B (en) * 2015-08-10 2019-03-15 贵州扬生医用器材有限公司 A kind of surgical flush fluid and its preparation method
KR101666792B1 (en) 2016-02-05 2016-10-17 주식회사 파마리서치프로덕트 Thermosensitive hydrogel composition containing nucleic acid and chitosan
CN105860107B (en) * 2016-04-26 2018-02-09 中南大学 A kind of hydrogen peroxide response and the preparation method of the aquagel with electro-chemical activity
US11766386B2 (en) 2016-11-07 2023-09-26 3M Innovative Properties Company Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s)
JP2020502241A (en) * 2016-12-22 2020-01-23 オムリックス・バイオファーマシューティカルズ・リミテッドＯｍｒｉｘ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． Hemostatic composition containing anion exchanger and calcium salt
IL249725A0 (en) 2016-12-22 2017-03-30 Omrix Biopharmaceuticals Ltd Hemostatic composition comprising an anion exchanger and a calcium salt
JP6939607B2 (en) * 2017-03-27 2021-09-22 Jsr株式会社 Compositions and their uses
CN108926490B (en) * 2017-05-25 2021-01-26 南方医科大学南方医院 Manufacturing method of anticoagulation stomach tube
RU2675631C1 (en) * 2018-10-02 2018-12-21 Общество с ограниченной ответственностью "Новые Биомедицинские Решения" Local hemostatic agent with enhanced antimicrobial activity
US20220211902A1 (en) * 2019-04-03 2022-07-07 Dtech - Società A Responsabilità Limitata Two-component system for the therapeutic treatment of skin lesions and production method thereof
CN110157010B (en) * 2019-05-05 2021-04-02 上海交通大学 Polyelectrolyte complex hydrogel hemostatic based on polysaccharide/polypeptide
JP2020078729A (en) * 2020-03-04 2020-05-28 クレシロン， インコーポレイテッド Highly efficacious hemostatic adhesive polymer scaffold
CN111303453B (en) * 2020-03-09 2021-06-04 中国海洋大学 Preparation method and application of multiple sensitive hydrogel polymer
EP3925636A1 (en) 2020-06-17 2021-12-22 Centre Of Experimental Medicine Slovak Academy Of Sciences Institute Of Experimental Pharmacology Composite membranes containing a smart-released cytoprotectant targeting the inflamed tissue and use thereof
CN115887738A (en) * 2022-12-16 2023-04-04 湖南师范大学 Polyacrylamide-chitosan/kaolin porous material and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5836970A (en) * 1996-08-02 1998-11-17 The Kendall Company Hemostatic wound dressing
US6150581A (en) * 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
US20110144229A1 (en) * 2008-08-19 2011-06-16 The Regents Of The University Of Michigan Biocompatible coatings, and methods of making and using the same

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58206751A (en) 1982-05-26 1983-12-02 日石三菱株式会社 Wound covering material
JPS59139310A (en) 1983-01-31 1984-08-10 Shiseido Co Ltd Emulsified composition
JPH0612993B2 (en) 1987-08-10 1994-02-23 株式会社クラレ Method for producing spherical microbe-immobilized moldings
US4956350A (en) * 1988-08-18 1990-09-11 Minnesota Mining And Manufacturing Company Wound filling compositions
FI95207C (en) 1992-09-14 1996-01-10 Novasso Oy Wound Protective Side
JP3411602B2 (en) * 1992-10-22 2003-06-03 グンゼ株式会社 Chitosan dissolution method
DE4337152A1 (en) 1993-10-30 1995-05-04 Merck Patent Gmbh Process for the preparation of aqueous chitosan solutions and gels
US5670169A (en) 1993-12-20 1997-09-23 E.R. Squibb & Sons, Inc. Wound hydrating gel with novel preservative system and low cytotoxicity
US20020032488A1 (en) 1994-05-13 2002-03-14 Brekke John H. Device for regeneration of articular cartilage and other tissue
GB2328443B (en) * 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
WO1999034751A1 (en) 1998-01-06 1999-07-15 Sceusa Nicholas A A drug dosage form based on the teorell-meyer gradient
JP4241985B2 (en) * 1998-04-24 2009-03-18 株式会社クラレ Medical adhesive
US6200595B1 (en) 1998-04-24 2001-03-13 Kuraray Co., Ltd. Medical adhesive
JPH11318407A (en) * 1998-05-19 1999-11-24 Lion Corp Processed food
AU5279299A (en) 1998-08-31 2000-03-21 Coloplast A/S A composition capable of absorbing fluid
JP4267106B2 (en) * 1998-10-15 2009-05-27 株式会社クラレ Anti-adhesion material
JP4159682B2 (en) * 1998-12-22 2008-10-01 株式会社クラレ Hemostatic material
JP4149098B2 (en) 1999-09-13 2008-09-10 株式会社クラレ Process for producing water-swellable medical polymer gel and water-swellable medical polymer gel
US20030206958A1 (en) 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
JP4489437B2 (en) * 2002-02-21 2010-06-23 エンセル，インコーポレイテッド Immobilized bioactive hydrogel matrix as a surface coating
US7217426B1 (en) * 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
JP2004041586A (en) 2002-07-15 2004-02-12 Fujimori Kogyo Co Ltd Biocompatible material and production method used for the same
US7112713B2 (en) 2003-03-12 2006-09-26 Gelsus Research And Consulting, Inc. Dressing based on the Teorell-Meyer gradient
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
ES2384519T3 (en) * 2004-02-23 2012-07-06 Loma Linda University Medical Center Hemostatic agent for topical and internal use
US20050203058A1 (en) 2004-03-11 2005-09-15 Johnson Edwin L. Compositions of alpha- and beta-chitosan and methods of preparing them
US8021684B2 (en) * 2004-07-09 2011-09-20 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
MX2007000918A (en) 2004-07-22 2007-12-04 Hemo Nanoscience Llc Compositions and methods for treating excessive bleeding.
CN101563116A (en) * 2005-07-21 2009-10-21 Fmc生物聚合物联合股份有限公司 Medical devices coated with a fast dissolving biocompatible coating
KR20080067687A (en) * 2005-11-02 2008-07-21 아이리스 테라퓨틱스, 인코포레이티드 Polycation-polyanion complexes, compositions and methods of use thereof
CN100411690C (en) * 2006-01-17 2008-08-20 武汉理工大学 Bacteriostatic porous polyelectrolyte material and its prepn process
WO2007112446A2 (en) 2006-03-28 2007-10-04 University Of Washington Alginate-based nanofibers and related scaffolds
US20070237811A1 (en) * 2006-04-10 2007-10-11 Scherr George H Chitosan wound dressing
ITPD20060203A1 (en) * 2006-05-22 2007-11-23 Univ Degli Studi Trieste HYDROGELS OF POLYSACCHARID MIXTURES FOR TISSUE ENGINEERING AND THE VEHICLE OF ACTIVE COMPOUNDS
CN1883721A (en) * 2006-06-21 2006-12-27 哈尔滨工业大学 Method for modifying artificial implanter by covalent cross-linking gel
US7935363B2 (en) * 2006-12-12 2011-05-03 Synthasome, Inc. Composite material for tissue repair
EP3000487B8 (en) 2007-02-19 2022-06-15 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
EP2163364B1 (en) 2007-06-11 2012-05-16 National University Corporation Kyoto Institute of Technology Method of processing plant
US20090041858A1 (en) 2007-08-06 2009-02-12 Cao Group, Inc. Haemostatic Compositions Thickened by Polymers Containing Nitrogen Moieties
CN101848739A (en) * 2007-08-28 2010-09-29 T·阿萨纳夏季斯 Surgical hydrogel
US20090123509A1 (en) 2007-11-08 2009-05-14 Cory Berkland Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds
US8283384B2 (en) * 2008-01-24 2012-10-09 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
AU2009240513B2 (en) * 2008-04-24 2015-03-26 Medtronic, Inc. Chitosan-containing protective composition
CN101463145A (en) * 2009-01-12 2009-06-24 武汉理工大学 Carboxymethyl chitosan / oxidized sodium alginate self-crosslinking antibacterial hydrogel material
CN101463144B (en) * 2009-01-12 2010-12-29 武汉理工大学 Preparation method of hydroxypropyl chitosan / oxidized sodium alginate self-crosslinking antibacterial hydrogel material
EP2416741B1 (en) 2009-04-06 2015-03-11 Bender Analytical Holding B.V. In situ gelling alginate systems
KR101103423B1 (en) * 2009-09-04 2012-01-06 아주대학교산학협력단 In situ forming hydrogel for tissue adhesives and biomedical use thereof
EP2504039A4 (en) 2009-11-25 2014-07-02 Univ Loma Linda Med Chitosan-based hemostatic textile
WO2011075557A1 (en) * 2009-12-16 2011-06-23 The Trustees Of Columbia University In The City Of New York Methods, devices, and systems for on-demand ultrasound-triggered drug delivery
US8389498B2 (en) 2010-03-26 2013-03-05 Taiwan Textile Research Institute Spinning solution and method for manufacturing biomaterial fibers
US8968362B2 (en) 2010-04-08 2015-03-03 Covidien Lp Coated looped suture
EP2575906B1 (en) * 2010-05-24 2014-12-10 University of Utah Research Foundation Reinforced adhesive complex coacervates and methods of making and using thereof
EP2600910B1 (en) * 2010-08-05 2016-01-20 Lifebond Ltd Dry composition wound dressings and adhesives
CN102475691B (en) 2010-11-30 2014-04-16 中国科学院大连化学物理研究所 Alginate-chitosan acyl derivative microcapsule, its preparation and application
EA023546B1 (en) 2011-03-17 2016-06-30 Перма-Фикс Энвайронментал Сервисез, Инк. Preparation of chitosan-based microporous composite material and its applications
WO2012130031A1 (en) 2011-04-01 2012-10-04 广州奥托沙医药科技有限公司 Medical absorbable hemostatic material for bone wounds and preparation method therefor
GB2499359B (en) 2011-10-05 2016-12-28 Univ Of Bolton Polysaccharide fibres for wound dressings
AU2012334982A1 (en) * 2011-11-13 2014-05-22 Cresilon, Inc. In-situ cross-linkable polymeric compositions and methods thereof
US8895304B2 (en) 2011-12-09 2014-11-25 Acell, Inc. Hemostatic device
EP2928449B1 (en) 2012-12-10 2018-08-22 Regenics AS Use of egg cellular extracts for skin rejuvenation
EP2983718A4 (en) 2013-04-11 2016-12-07 Univ Of Vermont And State Agricultural College Decellularization and recellularization of whole organs
WO2016199624A1 (en) 2015-06-11 2016-12-15 株式会社村田製作所 Pump
WO2016209198A1 (en) 2015-06-22 2016-12-29 Cresilion, Inc. Highly efficacious hemostatic adhesive polymer scaffold

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150581A (en) * 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
US5836970A (en) * 1996-08-02 1998-11-17 The Kendall Company Hemostatic wound dressing
US20110144229A1 (en) * 2008-08-19 2011-06-16 The Regents Of The University Of Michigan Biocompatible coatings, and methods of making and using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gotah et al., Chemosphere, 2004, vol. 55, pages 135-140. *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913926B2 (en) 2008-01-24 2018-03-13 University Of Utah Research Foundation Adhesive complex coacervates and method of making and using thereof
US9272069B2 (en) 2008-01-24 2016-03-01 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
US10517987B2 (en) 2008-01-24 2019-12-31 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
US10653813B2 (en) 2010-05-24 2020-05-19 University Of Utah Research Foundation Reinforced adhesive complex coacervates and methods of making and using thereof
US9867899B2 (en) 2010-05-24 2018-01-16 University Of Utah Research Foundation Reinforced adhesive complex coacervates and methods of making and using thereof
US9421300B2 (en) 2010-11-12 2016-08-23 University Of Utah Research Foundation Simple coacervates and methods of use thereof
US9173971B2 (en) 2010-11-12 2015-11-03 University Of Utah Research Foundation Simple adhesive coacervates and methods of making and using thereof
US9999700B1 (en) 2010-11-12 2018-06-19 University Of Utah Research Foundation Simple coacervates and methods of use thereof
US10850003B2 (en) 2011-11-13 2020-12-01 Cresilon, Inc. In-situ cross-linkable polymeric compositions and methods thereof
US11383005B2 (en) 2011-11-13 2022-07-12 Cresilon, Inc. In-situ cross-linkable polymeric compositions and methods thereof
US10077324B2 (en) 2013-02-06 2018-09-18 Kci Licensing, Inc. Polymers, preparation and use thereof
US10729579B2 (en) * 2014-07-11 2020-08-04 National Institutes Of Health Surgical tool and method for ocular tissue transplantation
US11723799B2 (en) 2014-07-11 2023-08-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Surgical tool and method for soft ocular tissue transplantation
US20170128263A1 (en) * 2014-07-11 2017-05-11 National Institutes Of Health Surgical tool and method for ocular tissue transplantation
US10369249B2 (en) 2014-07-14 2019-08-06 University Of Utah Research Foundation In situ solidifying complex coacervates and methods of making and using thereof
US9913927B2 (en) 2014-07-14 2018-03-13 University Of Utah Research Foundation In situ solidifying complex coacervates and methods of making and using thereof
US10729807B2 (en) 2014-07-14 2020-08-04 University Of Utah Research Foundation In situ solidifying solutions and methods of making and using thereof
US11471557B2 (en) 2014-07-14 2022-10-18 University Of Utah Research Foundation In situ solidifying solutions and methods of making and using thereof
KR102518121B1 (en) * 2015-06-22 2023-04-05 크레실론, 인코퍼레이티드 Adhesive composition scaffold for high-efficiency hemostasis
KR20180053636A (en) * 2015-06-22 2018-05-23 크레실론, 인코퍼레이티드 High Efficiency Hemostatic Binding Adhesive Composition Scaffold
WO2016209198A1 (en) * 2015-06-22 2016-12-29 Cresilion, Inc. Highly efficacious hemostatic adhesive polymer scaffold
AU2015399459B2 (en) * 2015-06-22 2021-02-18 Cresilon, Inc. Highly efficacious hemostatic adhesive polymer scaffold
RU2750648C2 (en) * 2015-06-22 2021-06-30 Кресилон, Инк. High-efficiency haemostatic adhesive polymer frame
US10660945B2 (en) 2015-08-07 2020-05-26 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
US11065337B2 (en) 2015-12-14 2021-07-20 University of Pittsburgh—of the Commonwealth System of Higher Education Complex coacervate for controlled release and related methods
US11779647B2 (en) 2015-12-14 2023-10-10 University of Pittsburgh—of the Commonwealth System of Higher Education Complex coacervate for controlled release and related methods
US11298423B2 (en) * 2016-03-04 2022-04-12 University of Pittsburgh—of the Commonwealth System of Higher Education Protection and delivery of multiple therapeutic proteins
US11857631B2 (en) 2016-03-04 2024-01-02 University of Pittsburgh—of the Commonwealth System of Higher Education Protection and delivery of multiple therapeutic proteins
US11266678B2 (en) * 2016-08-25 2022-03-08 Pharmaresearch Co., Ltd. Composition for articular cavity injection comprising nucleic acid and chitosan
WO2018119320A1 (en) * 2016-12-21 2018-06-28 Cresilon, Inc. Hemostatic compositions with antifibrinolytic agents
US11541151B2 (en) 2017-09-20 2023-01-03 Cha University Industry-Academic Cooperation Foundation Coacervate composition containing protein drug and wound healing agent comprising same
US20190328933A1 (en) * 2018-01-26 2019-10-31 Polarityte, Inc. Composite-interfacing biomaterial accelerant substrate
US11896234B2 (en) 2018-01-26 2024-02-13 Fluidx Medical Technology, Llc Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion

Also Published As

Publication number Publication date
US20170266339A1 (en) 2017-09-21
US20210290817A1 (en) 2021-09-23
HK1201734A1 (en) 2015-09-11
SG10201610469QA (en) 2017-02-27
WO2013071235A1 (en) 2013-05-16
IL232330A0 (en) 2014-06-30
US9687584B1 (en) 2017-06-27
EP2776068A4 (en) 2015-05-20
SG11201402279SA (en) 2014-06-27
MX2019008051A (en) 2019-09-09
JP2014533181A (en) 2014-12-11
AU2012334982A1 (en) 2014-05-22
KR20140090670A (en) 2014-07-17
BR112014011442A8 (en) 2018-01-09
US10850003B2 (en) 2020-12-01
MX366366B (en) 2019-07-05
AU2017219007A1 (en) 2017-09-07
MX2014005738A (en) 2014-07-09
RU2017144044A (en) 2019-02-15
BR112014011442A2 (en) 2017-05-16
IN2014CN03524A (en) 2015-10-09
CA2855347C (en) 2019-03-05
ZA201403166B (en) 2015-11-25
RU2640084C2 (en) 2017-12-26
IL232330B (en) 2019-06-30
CN103930133A (en) 2014-07-16
RU2014124157A (en) 2015-12-27
US20170157286A1 (en) 2017-06-08
JP2021007754A (en) 2021-01-28
JP7013336B2 (en) 2022-01-31
JP2018183611A (en) 2018-11-22
US11383005B2 (en) 2022-07-12
CA2855347A1 (en) 2013-05-16
WO2013071235A9 (en) 2013-07-18
EP2776068A1 (en) 2014-09-17
CN109602944A (en) 2019-04-12

Similar Documents

Publication Publication Date Title
US11383005B2 (en) In-situ cross-linkable polymeric compositions and methods thereof
Shah et al. Biopolymer-based biomaterials for accelerated diabetic wound healing: A critical review
Graça et al. Hyaluronic acid—Based wound dressings: A review
Arif et al. Polymer-based biomaterials for chronic wound management: Promises and challenges
Kamoun et al. A review on polymeric hydrogel membranes for wound dressing applications: PVA-based hydrogel dressings
Kurakula et al. Alginate-based hydrogel systems for drug releasing in wound healing
Moura et al. Recent advances on the development of wound dressings for diabetic foot ulcer treatment—A review
Ji et al. Advances in chitosan-based wound dressings: Modifications, fabrications, applications and prospects
Mercy et al. Chitosan-derivatives as hemostatic agents: Their role in tissue regeneration
Ghadi et al. Microparticulate polymers and hydrogels for wound healing
Gokarneshan Application of natural polymers and herbal extracts in wound management
Zahra et al. Exploring the recent developments of alginate silk fibroin material for hydrogel wound dressing: A review
Yaşayan et al. Natural polymers for wound dressing applications
Davis et al. Passive and interactive dressing materials
Pal Kaur et al. Material couture for wound healing and regeneration: an overview
Shi et al. Recent progresses of collagen dressings for chronic skin wound healing
Islam et al. Chitosan and chitosan-based biomaterials for wound management
Khalid et al. Polysaccharide composites as a wound-healing sponge
NZ723969B2 (en) In-situ cross-linkable polymeric compositions and methods thereof
NZ723969A (en) In-situ cross-linkable polymeric compositions and methods thereof
Yang et al. Effect of natural polymer materials on skin healing based on internal wound microenvironment: a review
Wahid Polysaccharide Composites as a Wound-Healing Sponge
Kebria et al. Polymers in wound repair and skin regeneration
Zhang et al. Advances of biological macromolecules hemostatic materials: A review
Li et al. Application of Hydrogel in Skin Repair

Legal Events

Date Code Title Description
AS Assignment

Owner name: SUNERIS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LANDOLINA, JOSEPH A.;REEL/FRAME:032861/0768

Effective date: 20140508

Owner name: SUNERIS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LANDOLINA, JOSEPH A;REEL/FRAME:032861/0443

Effective date: 20140508

AS Assignment

Owner name: CRESILON, INC., NEW YORK

Free format text: CHANGE OF NAME;ASSIGNOR:SUNERIS, INC.;REEL/FRAME:040029/0696

Effective date: 20160816

Owner name: CRESILON, INC., NEW YORK

Free format text: CHANGE OF NAME;ASSIGNOR:SUNERIS, INC.;REEL/FRAME:040029/0810

Effective date: 20160816

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION